PEN Share Price | Penumbra, Inc. Stock Analysis & Recommendation

Q: How big is Penumbra, Inc.?

Market Cap: As of Jun 18, Penumbra, Inc. has a market capitalization of 9,911.90 million, categorizing it as a Mid Cap company.Recent Quarterly Performance: For the latest four quarters, Penumbra, Inc. reported net sales of 1,240.10 million and a net profit of 42.23 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 1,150.93 million and total assets of 1,533.18 million.

Q: What does Penumbra, Inc. do?

Overview:Penumbra, Inc. is a healthcare company focused on interventional therapies within the Pharmaceuticals & Biotechnology industry, specifically targeting neuro and peripheral vascular medical conditions.Financial Snapshot:- Most recent Net Sales: 324 Million (Quarterly Results - Mar 2025)- Most recent Net Profit: 39 Million (Quarterly Results - Mar 2025)- Market cap: USD 9,911.90 Million (Mid Cap)Key Metrics:- P/E: 84.00- Dividend Yield: 0.00%- Debt Equity: -0.30- Return on Equity: 9.83%- Price to Book: 8.17Contact Details:- Address: 1 Penumbra, ALAMEDA CA : 94502-7676- Tel: 1 510 9952486- Website: http://www.penumbrainc.com/

Q: Is Penumbra, Inc. technically bullish or bearish?

As of 4 September 2025, the technical trend for Penumbra, Inc. has changed from sideways to mildly bullish. The weekly and monthly MACD indicators are bullish, while the KST shows a mildly bullish stance on the weekly and bullish on the monthly. Dow Theory also supports a mildly bullish outlook in both time frames. However, the daily moving averages indicate a mildly bearish trend, and the OBV is mildly bullish weekly but bearish monthly. In terms of performance, Penumbra has returned 31.79% over the past year, significantly outperforming the S&P 500's 17.14%, but has lagged behind the index over the 3-year and 5-year periods. Overall, the current technical stance is mildly bullish, driven by the MACD and KST indicators.

Q: Is Penumbra, Inc. overvalued or undervalued?

As of 21 November 2025, Penumbra, Inc. has moved from an expensive to a very expensive valuation grade. The company appears to be overvalued based on its current metrics. Key ratios include a P/E ratio of 84, an EV to EBITDA of 69.41, and a PEG ratio of 6.49, all of which significantly exceed industry norms. Comparatively, Hologic, Inc. has a P/E of 21.83 and an EV to EBITDA of 14.71, indicating that Penumbra is trading at a premium relative to its peers.Despite its strong recent performance, with a year-to-date return of 25.53% compared to the S&P 500's 12.26%, the high valuation ratios suggest that the stock may not be justified at its current price level. Overall, the combination of elevated valuation metrics and the shift in grade indicates that Penumbra, Inc. is overvalued in the current market environment.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

398.95 k

Shareholding (Dec 2025)

FII

10.59%

Held by 193 FIIs

DII

31.17%

Held by 64 DIIs

Promoter

0.14%

How big is Penumbra, Inc.?

22-Jun-2025

As of Jun 18, Penumbra, Inc. has a market capitalization of $9.91 billion, with recent net sales of $1.24 billion and a net profit of $42.23 million. The company reported shareholder's funds of $1.15 billion and total assets of $1.53 billion as of Dec 24.

View full answer

What does Penumbra, Inc. do?

22-Jun-2025

Penumbra, Inc. is a healthcare company specializing in interventional therapies for neuro and peripheral vascular conditions, with recent net sales of $324 million and a market cap of approximately $9.91 billion. Key financial metrics include a P/E ratio of 84.00 and a return on equity of 9.83%.

View full answer

Who are in the management team of Penumbra, Inc.?

22-Jun-2025

As of March 2022, the management team of Penumbra, Inc. includes Chairman and CEO Adam Elsesser, Chief Innovator Dr. Arani Bose, and several Independent Directors: Harpreet Grewal, Don Kassing, Janet Leeds, Bridget O'Rourke, and Surbhi Sarna. They are responsible for the company's strategic direction and operations.

View full answer

Is Penumbra, Inc. technically bullish or bearish?

20-Sep-2025

As of September 4, 2025, Penumbra, Inc. shows a mildly bullish technical trend, supported by bullish MACD and KST indicators, despite some bearish signals in daily moving averages and mixed performance compared to the S&P 500.

View full answer

Is Penumbra, Inc. overvalued or undervalued?

25-Nov-2025

As of November 21, 2025, Penumbra, Inc. is considered overvalued with a very expensive valuation grade, reflected in its high P/E ratio of 84 and EV to EBITDA of 69.41, significantly exceeding industry averages, despite a strong year-to-date return of 25.53%.

View full answer

Compare Penumbra, Inc. with Similar Stocks

Teleflex, Inc.Insulet Corp.EXACT Sciences Corp.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Company has a low Debt to Equity ratio (avg) at times

Healthy long term growth as Net Sales has grown by an annual rate of 19.41%

With a growth in Operating Profit of 624.09%, the company declared Very Positive results in Jun 25

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 13,194 Million (Small Cap)

P/E

80.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.33

Return on Equity

12.07%

Price to Book

9.71

Revenue and Profits:

Net Sales:

385 Million

(Quarterly Results - Dec 2025)

Net Profit:

47 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

9.29%

6 Months

31.88%

1 Year

22.43%

2 Years

52.15%

3 Years

28.52%

4 Years

60.52%

5 Years

17.88%

Penumbra, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

19.88%

EBIT Growth (5y)

55.68%

EBIT to Interest (avg)

30.18

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.30

Sales to Capital Employed (avg)

0.95

Tax Ratio

15.70%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

5.25%

ROE (avg)

3.85%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

9.71

EV to EBIT

73.73

EV to EBITDA

65.76

EV to Capital Employed

14.09

EV to Sales

9.55

PEG Ratio

1.66

Dividend Yield

ROCE (Latest)

19.12%

ROE (Latest)

12.07%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

No Trend

Bullish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 112 Schemes (57.84%)

Foreign Institutions

Held by 193 Foreign Institutions (10.59%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 22.16% vs 10.82% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 40.36% vs -37.82% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "385.40",
          "val2": "315.50",
          "chgp": "22.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "63.70",
          "val2": "50.70",
          "chgp": "25.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.30",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "47.30",
          "val2": "33.70",
          "chgp": "40.36%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "153.70%",
          "val2": "135.60%",
          "chgp": "1.81%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 17.50% vs 12.86% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 1,169.29% vs -84.62% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,403.70",
          "val2": "1,194.60",
          "chgp": "17.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "210.30",
          "val2": "113.50",
          "chgp": "85.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.30",
          "val2": "1.40",
          "chgp": "-7.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-76.90",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "177.70",
          "val2": "14.00",
          "chgp": "1,169.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "134.80%",
          "val2": "72.20%",
          "chgp": "6.26%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

385.40

315.50

22.16%

Operating Profit (PBDIT) excl Other Income

63.70

50.70

25.64%

Interest

0.30

Exceptional Items

0.00

Consolidate Net Profit

47.30

33.70

40.36%

Operating Profit Margin (Excl OI)

153.70%

135.60%

1.81%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 22.16% vs 10.82% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 40.36% vs -37.82% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

1,403.70

1,194.60

17.50%

Operating Profit (PBDIT) excl Other Income

210.30

113.50

85.29%

Interest

1.30

1.40

-7.14%

Exceptional Items

0.00

-76.90

100.00%

Consolidate Net Profit

177.70

14.00

1,169.29%

Operating Profit Margin (Excl OI)

134.80%

72.20%

6.26%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 17.50% vs 12.86% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 1,169.29% vs -84.62% in Dec 2024

All Annual Results

Company CV

About Penumbra, Inc.

Penumbra, Inc.

Pharmaceuticals & Biotechnology

Penumbra, Inc. is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures. It focuses on developing, manufacturing and marketing products for use by specialist physicians, including interventional neuroradiologists, neurosurgeons, interventional neurologists, interventional radiologists and vascular surgeons. Its neuro products include Neurovascular Access, Neuro Thrombectomy (Ischemic Stroke), Neurovascular Embolization (Brain Aneurysms) and Neurosurgical Tools (Hemorrhagic Stroke). Its peripheral vascular products include Peripheral Vascular Embolization and Peripheral Thrombectomy.

Company Coordinates

Company Details

1 Penumbra , ALAMEDA CA : 94502-7676

Tel: 1 510 9952486

http://www.penumbrainc.com/

Registrar Details